Acute coronary syndrome: The effect of platelet inhibitors varies greatly
Medical University of Vienna News Sep 09, 2017
Platelet inhibiting treatments with P2Y12 antagonists given following acute coronary syndrome to prevent the formation a thrombus in a coronary artery can produce very different results, depending upon the drug that is used. The cumulative incidence of a further hospital stay for acute coronary syndrome or death within a two-year period was 18.7% for patients treated with clopidogrel, 8.7% for patients treated with prasugrel and 12% for those treated with ticagrelor. This was reported by lead author of the study, Safoura Sheikh Rezaei, junior doctor for internal medicine at MedUni Vienna, speaking about the study presented at the European Society of Cardiology (ESC) Congress.
The coded data of 72,676 patients discharged following a hospital stay with a diagnosis of acute coronary syndrome in the years 2009 Â 2014, were evaluated. The analysis included 32,830 patients with a first prescription of a P2Y12 inhibitor within the first 30 days following the index diagnosis of acute coronary syndrome. The percentage of patients treated with clopidogrel, prasugrel or ticagrelor was 56.8%, 20.4% and 22.9% respectively. The average duration of treatment was 12 months. 4,975 events occurred in 32,174 patients within a follow-up period of 25 months.
"The average duration of treatment with P2Y12 antagonists in patients with acute coronary syndrome in Austria corresponds to the European guidelines on drug treatment following acute coronary syndrome," explained Safoura Sheikh Rezaei. "It would appear that there is a lower incidence of cardiac events in patients treated with prasugrel and ticagrelor, which have increasingly been used since they came onto the market, as opposed to clopidogrel. Clopidogrel is still frequently used for patients at risk of bleeding complications or interactions."
According to the study author, the optimum duration of treatment with P2Y12 inhibitors is somewhat controversial when it comes to the benefits, bleeding risk and drug costs: "The purpose of our epidemiological study was to investigate the duration of treatment and number of new cardiac events in Austrian patients after acute coronary syndrome."
Go to Original
The coded data of 72,676 patients discharged following a hospital stay with a diagnosis of acute coronary syndrome in the years 2009 Â 2014, were evaluated. The analysis included 32,830 patients with a first prescription of a P2Y12 inhibitor within the first 30 days following the index diagnosis of acute coronary syndrome. The percentage of patients treated with clopidogrel, prasugrel or ticagrelor was 56.8%, 20.4% and 22.9% respectively. The average duration of treatment was 12 months. 4,975 events occurred in 32,174 patients within a follow-up period of 25 months.
"The average duration of treatment with P2Y12 antagonists in patients with acute coronary syndrome in Austria corresponds to the European guidelines on drug treatment following acute coronary syndrome," explained Safoura Sheikh Rezaei. "It would appear that there is a lower incidence of cardiac events in patients treated with prasugrel and ticagrelor, which have increasingly been used since they came onto the market, as opposed to clopidogrel. Clopidogrel is still frequently used for patients at risk of bleeding complications or interactions."
According to the study author, the optimum duration of treatment with P2Y12 inhibitors is somewhat controversial when it comes to the benefits, bleeding risk and drug costs: "The purpose of our epidemiological study was to investigate the duration of treatment and number of new cardiac events in Austrian patients after acute coronary syndrome."
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty -
Paid Market Research Surveys -
Case discussions, News & Journals' summaries
